Ide Shotaro, Sakamoto Noriho, Hara Shintaro, Hara Atsuko, Kakugawa Tomoyuki, Nakamura Yoichi, Futsuki Yoji, Izumikawa Koichi, Ishimatsu Yuji, Yanagihara Katsunori, Mukae Hiroshi
Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Intern Med. 2017;56(1):79-83. doi: 10.2169/internalmedicine.56.7380. Epub 2017 Jan 1.
Although pneumothorax has been reported to be a major pulmonary adverse event in patients treated with pazopanib, a multikinase inhibitor, drug-induced interstitial lung disease (DILD) has not been reported. A 74-year-old Japanese man who received pazopanib for the treatment of femoral leiomyosarcoma and lung metastasis presented with dyspnea and fatigue. He had mild interstitial pneumonia when pazopanib treatment was initiated. Chest computed tomography revealed progressive bilateral ground-glass opacity (GGO) and traction bronchiectasis. We diagnosed DILD due to pazopanib. The patient's pazopanib treatment was interrupted and a steroid was administered. The symptoms and GGO were improved with treatment. Physicians should be aware of DILD due to pazopanib in patients with pre-existing interstitial lung disease.
虽然据报道气胸是接受多激酶抑制剂帕唑帕尼治疗的患者的主要肺部不良事件，但药物性间质性肺病（DILD）尚未见报道。一名74岁的日本男性因股部平滑肌肉瘤和肺转移接受帕唑帕尼治疗，出现呼吸困难和疲劳。开始帕唑帕尼治疗时他有轻度间质性肺炎。胸部计算机断层扫描显示双侧进行性磨玻璃影（GGO）和牵拉性支气管扩张。我们诊断为帕唑帕尼所致的DILD。患者的帕唑帕尼治疗中断并给予类固醇治疗。治疗后症状和GGO有所改善。医生应意识到在已有间质性肺病的患者中帕唑帕尼可导致DILD。
